TABLE 1.
Peptide inhibitor sequences used in the present work and their MICs
| Peptide | Sequencea | MIC (μM)b |
|---|---|---|
| PAsmrFL | Ac-A-(Sar)3 -DPAALL GI G LI IA GV LVIQLFS-KKKKK-NH2 | >64 |
| PAsmrTM4 | Ac-A-(Sar)3 -LL GI G LI IA GV LV-KKK-NH2 | 16 |
| PAsmrDc | Ac-a-(Sar)3 -ll gi g li ia gv lv-kkk-NH2 | 32 |
| PAsmrScr | Ac-A-(Sar)3 -LLVLGAIGIIGLV-KKK-NH2 | >64 |
| PAsmrW | Ac-A-(Sar)3 -LL GI G LI WA GV LV-KKK-NH2 | >64 |
a
Sequences for full-length (FL) TM4 (residues 84 to 105) and shortened TM4 (residues 88 to 100) from PAsmr are shown, along with solubility tags, where Ac is an acetylated N terminus, NH2 is an amidated C terminus, and Sar (sarcosine) is N-methyl-glycine. The TM4-TM4 dimerization motif is underlined.
b
MICs determined against E. coli BL21 cells cloned with PAsmr.
c
Peptide is composed of d-enantiomeric amino acids, as indicated by the lowercase letters.